Pyxis Oncology Inc (PYXS)

The total asset value of Pyxis Oncology Inc (PYXS) stood at $ 194 Mln as on 31-Mar-23

The share price of Pyxis Oncology Inc (PYXS) is $1.51 (NASDAQ) as of 28-Nov-2023 16:00 EST. Pyxis Oncology Inc (PYXS) has given a return of -0.66% in the last 1 years.

Pyxis Oncology Inc (PYXS) has a market capitalisation of $ 115 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

The P/B ratio of Pyxis Oncology Inc (PYXS) is 0.22 times as on 09-Jun-2023, a -0.91% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Pyxis Oncology Inc (PYXS) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Pyxis Oncology Inc (PYXS) and enter the required number of quantities and click on buy to purchase the shares of Pyxis Oncology Inc (PYXS).

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

The CEO & director of Mr. John L. Flavin M.B.A., MBA, Ph.D.. is Pyxis Oncology Inc (PYXS), and CFO & Sr. VP is Dr. Lara S. Sullivan M.D., MBA.

The promoters of Pyxis Oncology Inc (PYXS) have pledged 0% of the total equity as on Dec-22.

Some of the close peers are:

No, TTM profit after tax of Pyxis Oncology Inc (PYXS) was $-72 Mln.